Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.

@article{RorickKehn2005ImprovedBO,
  title={Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.},
  author={Linda M. Rorick-Kehn and Everett J Perkins and Karen M. Knitowski and J. C. Hart and Michael P. Johnson and Darryle D. Schoepp and David L. Mckinzie},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2005},
  volume={316 2},
  pages={
          905-13
        }
}
Numerous studies have indicated that selective agonists of group II metabotropic glutamate (mGlu) receptors, such as LY354740 [(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate] and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], may be useful in the treatment of many psychiatric disorders, including psychosis, anxiety, and drug withdrawal. Although animal and human studies demonstrate potential therapeutic utility, poor oral bioavailability is a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

metabotropic glutamate receptors

  • DD Schoepp, GJ Marek
  • 2002
Highly Influential
5 Excerpts

bioavailability following 5 mg/kg (p.o.) dose of LY544344

  • b From Bueno
  • 2005

bioavailability following 30 mg/kg (p.o.) dose of LY354740

  • a From Johnson
  • 2002

Similar Papers

Loading similar papers…